• Home
  • Search Results

Search Results

Young Adult (18-34)
Cancer
418 studies match your search
Open

A Low-Dose Tamoxifen Trial for Early Breast Cancer

Do you have early-stage breast cancer that is considered low-risk by your doctor? If yes, you might be able to join a research study. In this study, we are testing if taking a lower dose of the medicine tamoxifen is a better treatment for you than the usual hormone therapy.

Age & Gender
  • 18 years ~ 99 years
  • Female
Study Interest
  • Cancer (Breast)
  • Women's Health
Open

The SAPPHO Study: A Single-Arm, Phase II Study of Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

Have you been diagnosed with Stage 4 HER2 positive (HER2+) breast cancer? If so, you may be able to take part in a research study to test the safety and effectiveness of a sequence of drugs (a taxane plus trastuzumab plus pertuzumab followed by trastuzumab Deruxtecan, followed by tucatinib plus Ado-trastuzumab emtansine (T-DM1), followed by trastuzumab plus pertuzumab plus tucatinib) to learn whether the treatment works in treating your type of cancer. The study will help us understand whether first intensifying therapy for a specific period and then stopping treatment is safe and effective for patients who receive this therapy.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Breast)
Open

The FoRtitude Interview Study

Are you a woman with a history of breast cancer (Stage 0-III)? Do you identify as Black/African-American? Do you struggle with fear or worry that your cancer may return? If you are a breast cancer survivor that identifies as Black/African-American, you may be eligible to participate in the FoRtitude Interview Study. Compensation provided.

Age & Gender
  • 18 years ~ 99 years
  • Female
Study Interest
  • Cancer (Breast)
  • Women's Health
Visit Location
100% Remote (online, phone, text)
Open

TReatment of ADC-Refractory Breast CancEr with Dato-DXd or T-DXd: TRADE DXd

Have you been diagnosed with HER2-low locally unresectable advanced or metastatic breast cancer? If so, you may be eligible for a study to investigate the efficacy treatment with Dato-DXd or T-DXd.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Breast)
Open

Ovarian Cancer Treatment

Have you been diagnosed with Ovarian Cancer? Have you received cytoreductive surgery? If so, you may be able to take part in a study on a new ovarian cancer treatment. We want to find out if taking a medicine called Olaparib for one year works as well as the usual treatment for ovarian cancer. We also want to see if Olaparib can help stop the cancer from growing or coming back.

Age & Gender
  • 18 years ~ 99 years
  • Female, Gender Inclusive
Study Interest
  • Cancer (Uterine (endometrial), Ovarian)
  • Women's Health
Open

S2212-CIRB: Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study (NCT TBD)

Have you been diagnosed with early stage triple negative breast cancer and not yet received treatment? If so, you may be eligible for a trial comparing the use two different regimens of chemotherapy-immunotherapy treatments prior to surgery.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female
Study Interest
  • Cancer (Breast)
Open

A Study of YL201 in Patients With Advanced Solid Tumors

Do you have solid tumor of the lung or esophagus? Have the standard treatments for your condition been ineffective or not tolerable? If so, you may be eligible to participate in an early phase research study of the investigational drug YL201 as a possible treatment for advanced solid tumors.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Head and Neck, Lung)
Open

CHS-388-202- A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab

Have you been diagnosed with Hepatocellular Carcinoma (HCC), also referred to as Liver Cancer? If so, you may be a good fit for a clinical trial to evaluate how 3 drugs work in combination, and which dose is the best to treat your disease. The 3 drugs are casdozokitug (casdozo-key-tug), toripalimab (tor-i-pal-i- mab) and bevacizumab (bev-uh-siz-oo-mab).

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Colorectal)
  • Kidneys and Liver
Open

PROGRESS: Precision Oncology using Genomic Reflexive Evaluations for Study Selection and Survival

Have you been diagnosed with advanced breast, lung, colorectal, or bladder cancer and does your doctor plan to send a sample of your tumor for genetic testing? If so, then you may be able to take part in a research study that looks at whether an expert review of your tumor genetic test results can help your doctor identify better treatment options or clinical trials that may be suitable for your cancer.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Bladder, Breast, Colorectal, Lung)

Combination of XL092 and Cemiplimab in Anaplastic Thyroid Cancer

The purpose of this study is to look at the effectiveness of giving cemiplimab and XL092 before and after surgery for Anaplastic Thyroid Cancer.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Thyroid and Other Gland/Endocrine)
Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research